Roche has struck an exclusive global licensing agreement with Simcere Zaiming for SIM-0660, a preclinical trispecific T-cell engager targeting CD79a/CD19/CD3. The deal includes a $75 million upfront payment and total potential consideration of up to $1.53 billion tied to development, regulatory, and commercial milestones. Roche’s move is designed to fill a gap in its B-cell franchise and to extend its TCE pipeline with an asset aimed at B-cell-mediated diseases, including oncology and autoimmune indications. Simcere’s platform is positioned to drive potent T-cell-mediated killing while limiting cytokine-release toxicities that have challenged earlier TCE formats. The transaction underscores continued global appetite for next-generation trispecifics, and it adds another Chinese-origin asset to Roche’s out-licensing portfolio.